O	0	3	HIF	HIF	NN	B-NP
O	3	4	-	-	HYPH	I-NP
O	4	10	2alpha	2alpha	NN	I-NP
O	11	21	expression	expression	NN	I-NP
O	22	24	in	in	IN	B-PP
O	25	30	human	human	JJ	B-NP
B-Cell	31	36	fetal	fetal	JJ	I-NP
I-Cell	37	48	paraganglia	paraganglia	NN	I-NP
O	49	52	and	and	CC	I-NP
B-Cancer	53	66	neuroblastoma	neuroblastoma	NN	I-NP
O	66	67	:	:	:	O
O	68	76	relation	relation	NN	B-NP
O	77	79	to	to	TO	B-PP
O	80	91	sympathetic	sympathetic	JJ	B-NP
O	92	107	differentiation	differentiation	NN	I-NP
O	107	108	,	,	,	O
O	109	116	glucose	glucose	NN	B-NP
O	117	127	deficiency	deficiency	NN	I-NP
O	127	128	,	,	,	O
O	129	132	and	and	CC	O
O	133	140	hypoxia	hypoxia	NN	B-NP
O	140	141	.	.	.	O

B-Cancer	142	147	Solid	Solid	JJ	B-NP
I-Cancer	148	154	tumors	tumor	NNS	I-NP
O	155	158	are	be	VBP	B-VP
O	159	169	frequently	frequently	RB	B-NP
O	170	178	necrotic	necrotic	JJ	I-NP
O	179	182	and	and	CC	I-NP
O	183	190	hypoxic	hypoxic	JJ	I-NP
O	191	194	due	due	JJ	B-ADJP
O	195	197	to	to	TO	B-PP
O	198	202	poor	poor	JJ	B-NP
O	203	218	vascularization	vascularization	NN	I-NP
O	218	219	.	.	.	O

B-Cell	220	225	Tumor	Tumor	NN	B-NP
I-Cell	226	231	cells	cell	NNS	I-NP
O	232	237	adapt	adapt	VBP	B-VP
O	238	240	to	to	TO	B-PP
O	241	248	hypoxia	hypoxia	NN	B-NP
O	249	251	by	by	IN	B-PP
O	252	262	modulating	modulate	VBG	B-VP
O	263	268	their	their	PRP$	B-NP
O	269	278	phenotype	phenotype	NN	I-NP
O	278	279	.	.	.	O

O	280	283	Key	Key	NN	B-NP
O	284	291	players	player	NNS	I-NP
O	292	294	in	in	IN	B-PP
O	295	299	this	this	DT	B-NP
O	300	307	process	process	NN	I-NP
O	308	311	are	be	VBP	B-VP
O	312	315	the	the	DT	B-NP
O	316	323	hypoxia	hypoxia	NN	I-NP
O	323	324	-	-	HYPH	B-NP
O	324	333	inducible	inducible	JJ	I-NP
O	334	341	factors	factor	NNS	I-NP
O	342	343	(	(	(	O
O	343	346	HIF	HIF	NN	B-NP
O	346	347	-	-	HYPH	B-NP
O	347	353	1alpha	1alpha	NN	I-NP
O	354	356	to	to	TO	B-PP
O	357	363	3alpha	3alpha	NN	B-NP
O	363	364	)	)	)	O
O	364	365	.	.	.	O

O	366	370	HIFs	HIF	NNS	B-NP
O	371	374	are	be	VBP	B-VP
O	375	379	also	also	RB	I-VP
O	380	389	expressed	express	VBN	I-VP
O	390	396	during	during	IN	B-PP
O	397	403	normal	normal	JJ	B-NP
O	404	415	development	development	NN	I-NP
O	415	416	;	;	:	O
O	417	420	for	for	IN	B-PP
O	421	428	example	example	NN	B-NP
O	428	429	,	,	,	O
O	430	433	HIF	HIF	NN	B-NP
O	433	434	-	-	HYPH	I-NP
O	434	440	2alpha	2alpha	NN	I-NP
O	441	443	is	be	VBZ	B-VP
O	444	456	specifically	specifically	RB	I-VP
O	457	466	expressed	express	VBN	I-VP
O	467	470	and	and	CC	O
O	471	478	appears	appear	VBZ	B-VP
O	479	481	to	to	TO	I-VP
O	482	484	be	be	VB	I-VP
O	485	493	involved	involve	VBN	I-VP
O	494	496	in	in	IN	B-PP
O	497	500	the	the	DT	B-NP
O	501	512	development	development	NN	I-NP
O	513	515	of	of	IN	B-PP
O	516	519	the	the	DT	B-NP
O	520	526	murine	murine	JJ	I-NP
B-Anatomical_system	527	538	sympathetic	sympathetic	JJ	I-NP
I-Anatomical_system	539	546	nervous	nervous	JJ	I-NP
I-Anatomical_system	547	553	system	system	NN	I-NP
O	554	555	(	(	(	O
B-Anatomical_system	555	558	SNS	SNS	NN	B-NP
O	558	559	)	)	)	O
O	559	560	.	.	.	O

O	561	565	Here	Here	RB	B-ADVP
O	565	566	,	,	,	O
O	567	569	we	we	PRP	B-NP
O	570	581	demonstrate	demonstrate	VBP	B-VP
O	582	586	that	that	IN	B-SBAR
O	587	590	HIF	HIF	NN	B-NP
O	590	591	-	-	HYPH	B-NP
O	591	597	2alpha	2alpha	NN	I-NP
O	598	605	protein	protein	NN	I-NP
O	606	608	is	be	VBZ	B-VP
O	609	620	selectively	selectively	RB	B-ADJP
O	621	628	present	present	JJ	I-ADJP
O	629	631	in	in	IN	B-PP
O	632	637	human	human	JJ	B-NP
B-Developing_anatomical_structure	638	643	fetal	fetal	JJ	I-NP
O	644	648	week	week	NN	I-NP
O	649	650	8	8	CD	I-NP
O	650	651	.	.	.	O
O	651	652	5	5	CD	B-NP
B-Cell	653	656	SNS	SNS	NN	I-NP
I-Cell	657	668	paraganglia	paraganglia	NN	I-NP
O	668	669	.	.	.	O

B-Cancer	670	683	Neuroblastoma	Neuroblastoma	NN	B-NP
O	684	686	is	be	VBZ	B-VP
O	687	694	derived	derive	VBN	I-VP
O	695	699	from	from	IN	B-PP
B-Developing_anatomical_structure	700	703	SNS	SNS	NN	B-NP
I-Developing_anatomical_structure	704	714	precursors	precursor	NNS	I-NP
O	714	715	.	.	.	O

O	716	718	In	In	IN	B-PP
O	719	720	a	a	DT	B-NP
O	721	727	subset	subset	NN	I-NP
O	728	730	of	of	IN	B-PP
B-Cancer	731	745	neuroblastomas	neuroblastoma	NNS	B-NP
O	745	746	,	,	,	O
O	747	748	a	a	DT	B-NP
O	749	760	spontaneous	spontaneous	JJ	I-NP
B-Cell	761	769	neuronal	neuronal	JJ	I-NP
O	770	772	to	to	TO	B-PP
B-Cell	773	787	neuroendocrine	neuroendocrine	JJ	B-NP
O	788	803	differentiation	differentiation	NN	I-NP
O	804	810	occurs	occur	VBZ	B-VP
O	811	813	in	in	IN	B-PP
O	814	819	areas	area	NNS	B-NP
O	820	828	adjacent	adjacent	JJ	B-ADJP
O	829	831	to	to	TO	B-PP
B-Tissue	832	840	necrotic	necrotic	JJ	B-NP
I-Tissue	841	846	zones	zone	NNS	I-NP
O	846	847	.	.	.	O

O	848	850	As	As	IN	B-SBAR
O	851	854	HIF	HIF	NN	B-NP
O	854	855	-	-	HYPH	B-NP
O	855	861	2alpha	2alpha	NN	I-NP
O	862	870	activity	activity	NN	I-NP
O	871	874	has	have	VBZ	B-VP
O	875	879	been	be	VBN	I-VP
O	880	890	associated	associate	VBN	I-VP
O	891	894	not	not	RB	B-CONJP
O	895	899	only	only	RB	I-CONJP
O	900	904	with	with	IN	B-PP
O	905	912	hypoxic	hypoxic	JJ	B-ADJP
O	913	916	but	but	CC	B-CONJP
O	917	921	also	also	RB	I-CONJP
O	922	926	with	with	IN	B-PP
O	927	939	hypoglycemic	hypoglycemic	JJ	B-NP
O	940	950	conditions	condition	NNS	I-NP
O	950	951	,	,	,	O
O	952	954	we	we	PRP	B-NP
O	955	959	have	have	VBP	B-VP
O	960	972	investigated	investigate	VBN	I-VP
O	973	981	putative	putative	JJ	B-NP
O	982	989	effects	effect	NNS	I-NP
O	990	992	of	of	IN	B-PP
O	993	1000	hypoxia	hypoxia	NN	B-NP
O	1000	1001	,	,	,	O
O	1002	1009	glucose	glucose	NN	B-NP
O	1010	1019	depletion	depletion	NN	I-NP
O	1019	1020	,	,	,	O
O	1021	1024	and	and	CC	O
O	1025	1028	HIF	HIF	NN	B-NP
O	1028	1029	-	-	HYPH	B-NP
O	1029	1035	2alpha	2alpha	NN	I-NP
O	1036	1038	on	on	IN	B-PP
O	1039	1042	the	the	DT	B-NP
B-Cancer	1043	1056	neuroblastoma	neuroblastoma	NN	I-NP
O	1057	1066	phenotype	phenotype	NN	I-NP
O	1066	1067	.	.	.	O

O	1068	1071	HIF	HIF	NN	B-NP
O	1071	1072	-	-	HYPH	I-NP
O	1072	1078	2alpha	2alpha	NN	I-NP
O	1079	1082	was	be	VBD	B-VP
O	1083	1091	detected	detect	VBN	I-VP
O	1092	1094	in	in	IN	B-PP
O	1095	1102	hypoxic	hypoxic	JJ	B-ADJP
O	1103	1106	and	and	CC	O
O	1107	1109	in	in	IN	B-PP
O	1110	1114	well	well	RB	B-NP
O	1114	1115	-	-	HYPH	I-NP
O	1115	1125	oxygenized	oxygenize	VBN	I-NP
B-Cell	1126	1139	neuroblastoma	neuroblastoma	NN	I-NP
I-Cell	1140	1145	cells	cell	NNS	I-NP
O	1146	1149	and	and	CC	O
B-Tissue	1150	1156	tissue	tissue	NN	B-NP
O	1156	1157	,	,	,	O
O	1158	1168	presumably	presumably	RB	B-VP
O	1169	1179	reflecting	reflect	VBG	I-VP
O	1180	1185	their	their	PRP$	B-NP
B-Developing_anatomical_structure	1186	1195	embryonic	embryonic	JJ	I-NP
O	1196	1204	features	feature	NNS	I-NP
O	1204	1205	.	.	.	O

O	1206	1210	With	With	IN	B-PP
O	1211	1217	regard	regard	NN	B-NP
O	1218	1220	to	to	TO	B-PP
O	1221	1236	differentiation	differentiation	NN	B-NP
O	1236	1237	,	,	,	O
B-Cell	1238	1245	hypoxic	hypoxic	JJ	B-NP
I-Cell	1246	1251	cells	cell	NNS	I-NP
O	1252	1256	lost	lose	VBD	B-VP
O	1257	1262	their	their	PRP$	B-NP
B-Cell	1263	1271	neuronal	neuronal	JJ	I-NP
O	1271	1272	/	/	SYM	I-NP
B-Cell	1272	1286	neuroendocrine	neuroendocrine	JJ	I-NP
O	1287	1295	features	feature	NNS	I-NP
O	1296	1299	and	and	CC	O
O	1300	1306	gained	gain	VBD	B-VP
O	1307	1313	marker	marker	NN	B-NP
O	1314	1318	gene	gene	NN	I-NP
O	1319	1329	expression	expression	NN	I-NP
O	1330	1340	associated	associate	VBN	B-VP
O	1341	1345	with	with	IN	B-PP
O	1346	1348	an	an	DT	B-NP
O	1349	1357	immature	immature	JJ	I-NP
O	1357	1358	,	,	,	I-NP
B-Cell	1359	1365	neural	neural	JJ	I-NP
I-Cell	1366	1371	crest	crest	NN	I-NP
O	1371	1372	-	-	HYPH	B-NP
O	1372	1376	like	like	JJ	I-NP
O	1377	1386	phenotype	phenotype	NN	I-NP
O	1386	1387	.	.	.	O

O	1388	1391	Low	Low	JJ	B-NP
O	1392	1399	glucose	glucose	NN	I-NP
O	1400	1411	potentiated	potentiate	VBD	B-VP
O	1412	1415	the	the	DT	B-NP
O	1416	1422	effect	effect	NN	I-NP
O	1423	1425	of	of	IN	B-PP
O	1426	1433	hypoxia	hypoxia	NN	B-NP
O	1433	1434	.	.	.	O

O	1435	1440	These	These	DT	B-NP
O	1441	1449	findings	finding	NNS	I-NP
O	1450	1457	suggest	suggest	VBP	B-VP
O	1458	1462	that	that	IN	B-SBAR
O	1463	1469	poorly	poorly	RB	B-NP
O	1470	1482	vascularized	vascularize	VBN	I-NP
B-Cancer	1483	1497	neuroblastomas	neuroblastoma	NNS	I-NP
O	1498	1504	become	become	VBP	B-VP
O	1505	1513	immature	immature	JJ	B-ADJP
O	1514	1517	and	and	CC	O
O	1518	1526	maintain	maintain	VBP	B-VP
O	1527	1528	a	a	DT	B-NP
O	1529	1533	more	more	RBR	I-NP
O	1534	1544	aggressive	aggressive	JJ	I-NP
O	1545	1554	phenotype	phenotype	NN	I-NP
O	1554	1555	,	,	,	O
O	1556	1561	which	which	WDT	B-NP
O	1562	1570	possibly	possibly	RB	B-ADVP
O	1571	1576	could	could	MD	B-VP
O	1577	1584	involve	involve	VB	I-VP
O	1585	1586	a	a	DT	B-NP
O	1587	1596	sustained	sustained	JJ	I-NP
O	1597	1610	stabilization	stabilization	NN	I-NP
O	1611	1614	and	and	CC	I-NP
O	1615	1625	activation	activation	NN	I-NP
O	1626	1628	of	of	IN	B-PP
O	1629	1632	HIF	HIF	NN	B-NP
O	1632	1633	-	-	HYPH	B-NP
O	1633	1639	2alpha	2alpha	NN	I-NP
O	1639	1640	.	.	.	O

